Clinical trials: RANDOMIZED
Peripheral Vascular Disease, Peripheral Arterial Disease
EVERO Drug-coated Balloon (DCB) Randomized Trial
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero…
- Trial name
- NCT07144150
- Testing
- Evero DCB, Paclitaxel DCB
- Where
- 15 sites in United States
- Volunteers
- 410 people
- Sponsor
- Cook Research Incorporated
Thrombocytopaenia
A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
This was a worldwide, three-part (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension), multi-center study to evaluate the effect of eltrombopag in subjects with myelodysplastic syndromes (MDS) or acute…
- Trial name
- ASPIRE (NCT01440374)
- Testing
- eltrombopag
- Where
- 120 sites in United States, Argentina and 20 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Burn Injuries
Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.
The purpose is to compare time to healing using absorbent foam silver dressing (Mepilex Ag) compared to a silver sulfadiazine (SSD) 1% cream in the treatment of partial thickness burn injuries.284 in-patients in 8-12 centres in…
- Trial name
- NCT01439074
- Testing
- Mepilex Ag, Silver Sulphadiazine Ag cream
- Where
- 9 sites in China
- Volunteers
- 162 people
- Sponsor
- Molnlycke Health Care AB
Zika Virus
Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)
Double blinded, randomized, placebo-controlled, dose finding, multi-center, phase 1 trial in 48 healthy volunteer subjects. After completion of screening procedures, the subjects are randomized to one of four treatment groups…
- Trial name
- NCT02996890
- Testing
- MV-ZIKA
- Where
- 2 sites in Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Themis Bioscience GmbH
Adult Growth Hormone Deficiency
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
This is a multiple-dose, dose-escalation, randomized, double-blind, placebo-controlled phase Ⅱa clinical trial. A total of 36 adult participants with growth hormone deficiency will be enrolled sequentially in ascending dose…
- Trial name
- NCT07551804
- Testing
- Inpegsomatropin Injection
- Where
- 6 sites in China
- Volunteers
- 36 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Partial-thickness Skin Donor Sites
Altrazeal™ Versus Aquacel® Ag for Partial Thickness Skin Donor Sites
The primary objective of the study is to evaluate the time to wound healing in skin graft donor sites with a new treatment (Altrazeal dressing) compared to standard of care treatment (Aquacel Ag- Carboxymethylcellulose dressing)…
- Trial name
- NCT01062204
- Testing
- Altrazeal, Aquacel Ag
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- ULURU Inc.
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Crohn's Disease
Study Evaluating ERB-041 in Active Crohn's Disease
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.
- Trial name
- NCT00245947
- Testing
- ERB-041
- Volunteers
- 22 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Sclerosis, Relapsing Remitting
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
This is a randomized, double-blind, parallel group study comparing two doses of INT131( 3 mg and 1 mg) administered orally (PO) daily (QD) versus placebo 1 tablet PO QD in subjects with treatment-naïve RRMS for ≤ 3 years.
- Trial name
- NCT02638038
- Testing
- INT131
- Volunteers
- 228 people
- Sponsor
- InteKrin Therapeutics, Inc.
Migraine
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
The purpose of this study is to learn about the effects of Rimegepant to help prevent migraine. This study is seeking for participants who: Are male and female of 18 years of age or older.
- Trial name
- NCT05810038
- Testing
- Rimegepant
- Where
- 49 sites in China
- Volunteers
- 787 people
- Sponsor
- Pfizer
NSCLC
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
Patients in group A will receive DC-CTL treatment and chemotherapy. Patients in group B will receive only chemotherapy.
- Trial name
- NCT02766348
- Testing
- gemcitabine, DC-CTL, cisplatinum
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Intrauterine Synechiae, Tissue Adhesion, Surgery-Induced
The Efficacy and Safety of Medicurtain® in Patients With Hysteroscopy (Pivotal Study)
This study was designed to assess the safety and efficacy of MEDICURTAIN, an adhesion barrier in patients who underwent hysteroscopy with uterine polyp or endometrial myoma or missed abortion (uterine lesion suspected to be…
- Trial name
- NCT04638855
- Testing
- Medicurtain®
- Where
- South Korea
- Volunteers
- 223 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Adult Nocturnal Enuresis, Urinary Incontinence (UI)
This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.
This post-market study will assess the performance of and user experience with the PureWick™ System in a home setting. The study will also observe safety of the study device and collect information from participants about their…
- Trial name
- PUREST (NCT06666426)
- Testing
- PureWick System, Hollister Female Urinary Pouch External Collection Device
- Where
- 15 sites in United States
- Volunteers
- 171 people
- Sponsor
- C. R. Bard
Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
- Trial name
- NCT00097435
- Testing
- Albuferon, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 115 people
- Sponsor
- Human Genome Sciences Inc.
Primary Sjögren Syndrome
A Study of RSLV-132 in Females With Sjögren's Disease
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of SS in adults. It will also learn about the safety of RSLV-132.
- Trial name
- NCT06440525
- Testing
- RSLV-132
- Where
- 24 sites in United States
- Volunteers
- 106 people
- Sponsor
- Resolve Therapeutics
Healthy Subjects
Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects
This study will evaluate the effect of CYP3A weak inducer rufinamide on the pharmacokinetics (PK) of Quizartinib in healthy subjects
- Trial name
- NCT06740825
- Testing
- Quizartinib, Rufinamide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Psoriasis, Atopic Dermatitis
Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis
This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice daily for up to 28 days.
- Trial name
- NCT03381625
- Testing
- BMX-010
- Where
- 10 sites in United States
- Volunteers
- 139 people
- Sponsor
- BioMimetix JV, LLC
Post-Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
- Trial name
- MILESTONE℠ (NCT02271217)
- Testing
- dalfampridine-ER 7.5mg, dalfampridine-ER 10mg
- Where
- 74 sites in United States, Canada
- Volunteers
- 377 people
- Sponsor
- Acorda Therapeutics
Asthma
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Evaluate the superiority of CHF 5993 200/6/12.5 µg pressurised metered dose inhaler (pMDI) (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) versus CHF 1535 200/6 µg…
- Trial name
- TRIGGER (NCT02676089)
- Testing
- CHF 5993 200/6/12.5 µg, CHF 1535 200/6 µg, CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
- Where
- 244 sites in Argentina, Belarus and 15 more
- Volunteers
- 1,437 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.